Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels

American Journal of Geriatric Psychiatry

Volumn 24, Issue 11, 2016, Pages 1095-1104

  Babulal, Ganesh M ^a   Ghoshal, Nupur ^a   Head, Denise ^a   Vernon, Elizabeth K ^a   Holtzman, David M ^a   Benzinger, Tammie L S ^a   Fagan, Anne M ^a   Morris, John C ^a   Roe, Catherine M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; biomarkers; depression; mood; older adults

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PITTSBURGH COMPOUND B; TAU 181 PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANILINE DERIVATIVE; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; PHOSPHOPROTEIN; THIAZOLE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL DEMENTIA RATING; COGNITION; FEMALE; FOLLOW UP; GERIATRIC DEPRESSION SCALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE ASSESSMENT; MINI MENTAL STATE EXAMINATION; MOOD CHANGE; MOOD DISORDER; NEUROIMAGING; NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE; POSITRON EMISSION TOMOGRAPHY; PROFILE OF MOOD STATES; PROTEIN PHOSPHORYLATION; BRAIN; DEPRESSION; DIAGNOSTIC IMAGING; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOMARKERS; BRAIN; DEPRESSION; DEPRESSIVE DISORDER; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MOOD DISORDERS; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; THIAZOLES;

EID: 84992188111     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2016.04.004     Document Type: Article

References (39)

1. 1 Berger, A.-K., Fratiglioni, L., Forsell, Y., et al. The occurrence of depressive symptoms in the preclinical phase of AD A population-based study. Neurology 53 (1999), 1998–2002.
2. 2 Schmid, N.S., Taylor, K.I., Foldi, N.S., et al. Neuropsychological signs of Alzheimer's disease 8 years prior to diagnosis. J Alzheimers Dis 34 (2013), 537–546.
3. 3 Bartolini, M., Coccia, M., Luzzi, S., et al. Motivational symptoms of depression mask preclinical Alzheimer's disease in elderly subjects. Dement Geriatr Cogn Disord 19 (2004), 31–36.
4. 4 Bidzan, M., Bidzan, L., [Neurobehavioral manifestation in early period of Alzheimer disease and vascular dementia]. Psychiatr Pol 48 (2013), 319–330.
5. 5 Sperling, R.A., Aisen, P.S., Beckett, L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 280–292.
6. 6 Lavretsky, H., Siddarth, P., Kepe, V., et al. Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am J Geriatr Psychiatry 17 (2009), 493–502.
7. 7 Gustafson, D.R., Skoog, I., Rosengren, L., et al. Cerebrospinal fluid beta-amyloid 1–42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 78 (2007), 461–464.
8. 8 Roe, C.M., Fagan, A.M., Grant, E.A., et al. CSF biomarkers of Alzheimer disease “noncognitive” outcomes. Neurology 81 (2013), 2028–2031.
9. 9 McKhann, G.M., Knopman, D.S., Chertkow, H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 263–269.
10. 10 Burke, W.J., Miller, J.P., Rubin, E.H., et al. Reliability of the Washington University clinical dementia rating. Arch Neurol 45 (1988), 31–32.
11. 11 Morris, J.C., The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43 (1993), 2412–2414.
12. 12 Albert, M.S., DeKosky, S.T., Dickson, D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 270–279.
13. 13 O'Bryant, S.E., Waring, S.C., Cullum, C.M., et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol 65 (2008), 1091–1095.
14. 14 Folstein, M.F., Folstein, S.E., McHugh, P.R., “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975), 189–198.
15. 15 Klunk, W.E., Engler, H., Nordberg, A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004), 306–319.
16. 16 Su, Y., D'Angelo, G.M., Vlassenko, A.G., et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE, 8, 2013, e73377.
17. 17 Morris, J.C., Roe, C.M., Grant, E.A., et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66 (2009), 1469–1475.
18. 18 Storandt, M., Mintun, M.A., Head, D., et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-β peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Aβ deposition. Arch Neurol 66 (2009), 1476–1481.
19. 19 Fagan, A.M., Roe, C.M., Xiong, C., et al. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64 (2007), 343–349.
20. 20 Blennow, K., Zetterberg, H., Fagan, A.M., Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med, 2, 2012, a006221.
21. 21 Curran, S.L., Andrykowski, M.A., Studts, J.L., Short form of the Profile of Mood States (POMS-SF): psychometric information. Psychol Assess, 7, 1995, 80.
22. 22 Montorio, I., Izal, M., The Geriatric Depression Scale: a review of its development and utility. Int Psychogeriatr 8 (1996), 103–112.
23. 23 Kaufer, D.I., Cummings, J.L., Ketchel, P., et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12 (2000), 233–239.
24. 24 Wechsler, D., Stone, C.P., Wechsler Memory Scale Manual. 1973, Psychological Corporation, New York, NY.
25. 25 Grober, E., Buschke, H., Crystal, H., et al. Screening for dementia by memory testing. Neurology 38 (1988), 900–903.
26. 26 Chen, S.T., Siddarth, P., Saito, N.Y., et al. Psychological well-being and regional brain amyloid and tau in mild cognitive impairment. Am J Geriatr Psychiatry 22 (2014), 362–369.
27. 27 Amariglio, R.E., Mormino, E.C., Pietras, A.C., et al. Subjective cognitive concerns, amyloid-beta, and neurodegeneration in clinically normal elderly. Neurology 85 (2015), 56–62.
28. 28 Gudmundsson, P., Skoog, I., Waern, M., et al. The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry 15 (2007), 832–838.
29. 29 Masters, M.C., Morris, J.C., Roe, C.M., Noncognitive” symptoms of early Alzheimer disease: a longitudinal analysis. Neurology 84 (2015), 617–622.
30. 30 Ramakers, I.H.G.B., Verhey, F.R.J., Scheltens, P., et al. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med 43 (2013), 911–920.
31. 31 Kramberger, M.G., Jelic, V., Kåreholt, I., et al. Cerebrospinal fluid Alzheimer markers in depressed elderly subjects with and without Alzheimer's disease. Dement Geriatr Cogn Disord Extra 2 (2012), 48–56.
32. 32 Butters, M.A., Klunk, W.E., Mathis, C.A., et al. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord, 22, 2008, 261.
33. 33 Ghoshal, N., Garcı, F., Wuu, J., et al. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp Neurol 177 (2002), 475–493.
34. 34 Li, G., Sokal, I., Quinn, J., et al. CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69 (2007), 631–639.
35. 35 Fagan, A.M., Mintun, M.A., Shah, A.R., et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 1 (2009), 371–380.
36. 36 Vos, S.J.B., Xiong, C., Visser, P.J., et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 12 (2013), 957–965.
37. 37 Roe, C.M., Mintun, M.A., D'Angelo, G., et al. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11–labeled Pittsburgh Compound B uptake. Arch Neurol 65 (2008), 1467–1471.
38. 38 Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B (Methodol) 57 (1995), 289–300.
39. 39 McDonald, J.H., Handbook of Biological Statistics. 2009, Sparky House Publishing, Baltimore, MD.